Pulse.

a daily field guide to health research that matters

◆ Console

‹ Thu · 12 Nov 2026
Standard addition

First and Subsequent Major Cardiovascular Events With Oral Semaglutide in High-Risk Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial.

Oral semaglutide reduced both first and recurrent heart attacks and strokes in high-risk people with type 2 diabetes, lowering overall cardiovascular burden.

This secondary analysis of a randomized clinical trial examined First and Subsequent Major Cardiovascular Events With Oral Semaglutide in High-Risk Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial. Oral semaglutide reduced the risk of first plus subsequent 3-P MACE vs placebo, highlighting the benefit of oral semaglutide in reducing the total burden of clinical morbidity and mortality in this high-risk population.

What the study was

Study design
Secondary analysis of a randomized clinical trial
Sample size
9650
Category
Prevention
Maturity
Validated
Journal
JAMA cardiology

Why it surfaced

Retained after review of PubMed metadata and abstract because its secondary analysis of a randomized clinical trial directly informs cardiovascular-metabolic; scoring was capped conservatively for design and evidence maturity.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.